The 5 most recent market catalysts affecting $PALI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating on Palisade Bio (PALI) and maintained a $7 price target. This action sig…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 75
Proficient Auto Logistics Announces $75M Private Offering Of Convertible Senior Notes Due 2033 To Refinance Debt, Fund Capped Call; Settlement Expected August 13
This private offering of convertible senior notes by Proficient Auto Logistics (PALI) is a significant corporate finance event. The primary purpose is to refinance existing debt, w…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 65
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
Oppenheimer initiated coverage on Palisade Bio (PALI) with a 'Buy' rating and a price target of $8, citing the potential of its lead drug PALI-2108 in the inflammatory bowel diseas…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
Palisade Bio shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $8 price target.
This headline represents a significant corporate catalyst for Palisade Bio. Analyst initiation with a strong 'Outperform' rating and a substantial price target (implying significan…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 65
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8
Oppenheimer's initiation of coverage on Palisade Bio with an 'Outperform' rating and an $8 price target is a significant event for the company. This provides a vote of confidence f…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.